13F Holdings
中文EN

REPL Replimune Group, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737953 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY12.6%
TTM EPS YoY19.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-115.8%
ROA-71.0%
ROIC (approx.)-209.7%
Asset turnover—

Leverage & solvency

Liabilities / assets45.2%
Debt / equity0.49x
Current ratio7.11x
Interest coverage-30.18x

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue————————
R&D expense$34.37M$49.28M$52.32M$53.14M$57.88M$57.84M$53.98M$48.00M
SG&A expense$21.92M$18.97M$21.01M$18.73M$26.41M$32.58M$25.35M$18.02M
Operating income-$56.28M-$68.25M-$73.34M-$71.87M-$84.29M-$90.42M-$79.33M-$66.02M
Interest expense$2.52M$2.58M$2.37M$1.47M$1.49M$1.48M$1.46M$1.45M
Pretax income——-$73.46M-$71.24M——-$74.24M-$65.77M
Income tax——-$240,000-$311,000$0$0-$107,000$575,000
Net income-$57.12M-$69.77M-$73.22M-$70.93M-$83.10M-$86.69M-$74.13M-$66.34M
EBITDA-$55.48M-$67.31M-$72.57M-$71.07M-$83.49M-$89.55M-$78.48M-$65.02M
EPS (basic)-0.54-0.72—-0.77-0.90-0.95—-0.79
EPS (diluted)-0.54-0.72—-0.77-0.90-0.95—-0.79
Weighted avg. shares (diluted)105.18M96.86M—92.19M91.92M91.52M—83.50M
Balance sheet
Cash & equivalents$307.83M$185.36M$209.02M$122.95M$104.00M$99.08M$112.82M$173.94M
Short-term investments$0$9.97M$59.87M$146.19M$221.35M$305.97M$372.69M$364.29M
Inventory$9.87M—$0—————
Current assets$324.04M$200.81M$279.12M$280.35M$333.75M$413.37M$495.88M$547.58M
PP&E, net$10.70M$11.86M$12.97M$13.85M$14.71M$14.68M$13.74M$13.62M
Total assets$373.94M$252.45M$332.39M$333.59M$389.45M$469.51M$551.33M$603.63M
Current liabilities$45.55M$38.41M$58.23M$50.09M$52.90M$59.56M$62.36M$47.89M
Long-term debt$99.77M$84.11M$83.31M$47.63M$47.21M$46.79M$46.38M$45.96M
Total debt$99.77M$84.11M$83.31M$47.63M$47.21M$46.79M$46.38M$45.96M
Total liabilities$169.16M$146.80M$166.23M$123.05M$126.11M$132.79M$135.49M$121.25M
Shareholders' equity$204.78M$105.64M$166.16M$210.54M$263.34M$336.71M$415.84M$482.37M
Net debt-$208.07M-$101.25M-$125.72M-$75.32M-$56.80M-$52.29M-$66.44M-$127.98M
Shares outstanding94.81M83.98M82.72M79.63M78.40M77.81M77.09M77.01M
Cash flow statement
Operating cash flow-$47.70M-$75.73M-$56.16M-$65.95M-$81.21M-$77.02M-$53.73M-$50.71M
Capital expenditure$77,000$6,000$5,000$135,000$1.34M$2.74M$1.13M$1.80M
Free cash flow-$47.78M-$75.73M-$56.17M-$66.09M-$82.56M-$79.76M-$54.87M-$52.51M
Investing cash flow$9.76M$49.99M$86.51M$75.12M$84.17M$65.05M-$7.70M-$46.32M
Financing cash flow$160.55M$800,000$55.68M$10.45M$324,000-$158,000-$132,000$155.93M
Depreciation & amortization$800,000$937,000$769,000$800,000$800,000$873,000$848,000$1.00M
Stock-based compensation$10.54M$7.67M$8.12M$7.05M$8.34M$8.76M$8.28M$8.64M

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.